For example, the GLP-1 app is designed specifically to simplify this process
When GLP-1 medications slow gastrointestinal transit, fermentable carbohydrates remain exposed to gut microbes longer, increasing gas and bloating in susceptible individuals
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
The purpose of this registry is to collect information about the health of you and your baby
Monitoring Your Progress: The Blue Horizon Tiers When you are navigating both a thyroid condition and a new medication like a GLP-1, having a clear "snapshot" of your blood markers is incredibly helpful
The FDA's evaluation of GLP-1 receptor agonists has not identified colon cancer as a confirmed risk associated with this drug class
